证券代码：300676 证券简称：华大基因 公告编号：2025-059 深圳华大基因股份有限公司 关于 2026 年度开展外汇套期保值业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、交易额度及期限：深圳华大基因股份有限公司（以下简称公司）为提高公司应 对外汇波动风险的能力，降低汇率大幅波动对公司业绩的影响，增强财务稳健性，公司 及合并报表范围内的子公司 2026 年度拟继续与具有外汇套期保值业务经营资质的金融 机构开展外汇套期保值业务，交易品种包括但不限于远期结售汇、外汇掉期、外汇期权 等产品或上述产品的组合；预计任一交易日持有的最高合约价值不超过人民币 10 亿元 或等值外币（含本数，下同）。该额度自 2026 年 1 月 1 日至 2026 年 12 月 31 日的 12 个月内有效，在授权期限内可循环滚动使用。 2、已履行的审议程序：本事项已经公司第四届董事会第七次会议和第四届监事会 第七次会议审议通过，根据《深圳证券交易所上市公司自律监管指引第 7 号——交易与 关联交易》的规定，本议案尚需提交公司 2025 年第二次临 ...

证券代码：300676 证券简称：华大基因 公告编号：2025-061 深圳华大基因股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《深圳华大基因股份有限公司章程》（以 下简称《公司章程》）的有关规定，经深圳华大基因股份有限公司（以下简称公 司）第四届董事会第七次会议审议通过，公司董事会决定于2025年11月12日（星 期三）召开公司2025年第二次临时股东会。现就本次会议有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025年第二次临时股东会 2、股东会召集人：公司董事会 3、会议召开的合法性及合规性：经公司第四届董事会第七次会议审议通过， 决定召开2025年第二次临时股东会，召集程序符合有关法律、行政法规、部门规 章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025年11月12日（星期三）14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025年11月12日9:15-9:25， ...

证券代码：300676 证券简称：华大基因 公告编号：2025-055 深圳华大基因股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、深圳华大基因股份有限公司（以下简称公司）第四届监事会第七次会议 于2025年10月20日通过电子邮件形式送达至全体监事，通知中包括会议的相关材 料，同时列明了会议的召开时间、内容和方式。 2、本次监事会于2025年10月23日在公司会议室召开，以现场与通讯相结合 的方式进行表决（其中监事刘斯奇以通讯方式参加会议）。 3、本次监事会应参加表决监事3名，实际参加表决监事3名。 4、本次监事会由监事会主席刘斯奇先生召集和主持，公司董事会秘书和证 券事务代表列席了本次监事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《深圳华大基因股份有限公司章程》的有关规定。 二、监事会会议审议情况 《关于增加2025年度日常关联交易预计额度的公告》同日披露于巨潮资讯网。 表决结果：2票赞成，0票反对，0票弃权。 公司关联监事刘斯奇已对本议案回避 ...

2、本次董事会于2025年10月23日在公司会议室召开，以现场与通讯相结合 的方式进行表决（其中董事汪建、李宁、朱师达、张国成、杜兰、于李胜、侯志 波以通讯方式参加会议）。 3、本次董事会应参加表决董事9名，实际参加表决董事9名。 4、本次董事会由董事长汪建先生召集和主持，公司部分监事和高级管理人 员列席了本次董事会。 证券代码：300676 证券简称：华大基因 公告编号：2025-054 深圳华大基因股份有限公司 第四届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、深圳华大基因股份有限公司（以下简称公司）第四届董事会第七次会议 于2025年10月20日通过电子邮件形式送达至全体董事，通知中包括会议的相关材 料，同时列明了会议的召开时间、内容和方式。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以 下简称《公司法》）等法律法规和《深圳华大基因股份有限公司章程》（以下简 称《公司章程》）的有关规定。 二、董事会会议审议情况 1、审议通过《关于2025年第三季度报告的议案》 与会董事审议认 ...

华大基因公告，第三季度营收为10.42亿元，同比增长9.19%；净利润亏损2716.52万元，下降80.92%。 前三季度营收为26.74亿元，同比下降5.39%；净利润亏损2138.7万元，下降82.78%。 ...

Financial Performance - The company's revenue for Q3 2025 was ¥1,042,166,389.29, representing a 9.19% increase compared to the same period last year[3] - The net profit attributable to shareholders was -¥27,165,209.53, a decrease of 80.92% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥36,276,537.39, a decrease of 74.17% compared to the previous year[3] - For the first three quarters of 2025, the company achieved operating revenue of RMB 267,363.87 million, a year-on-year decrease of 5.39%[15] - The net profit attributable to shareholders for the same period was RMB -2,138.70 million, an increase of 82.78% year-on-year[15] - In Q3 2025, the company reported operating revenue of RMB 104,216.64 million, a year-on-year growth of 9.19%[15] - Total revenue for the current period is ¥2,673,638,742.11, a decrease of 5.37% from ¥2,825,935,926.99 in the previous period[30] - The net profit for the current period is -26,230,892.14, compared to -124,180,426.78 in the previous period, showing a significant improvement[31] - Operating profit for the current period is -35,804,257.97, an improvement from -119,699,288.76 in the previous period[31] - Total comprehensive income for the current period is -63,301,430.15, compared to -154,305,996.91 in the previous period, reflecting a reduction in losses[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,301,377,285.05, down 1.92% from the end of the previous year[3] - Total current assets decreased to ¥6,530,214,262.62 from ¥6,875,791,256.55, reflecting a decline of 5.02%[28] - Total non-current assets increased to ¥5,771,163,022.43 from ¥5,666,495,138.08, showing a growth of 1.85%[28] - Total liabilities decreased to ¥2,929,583,566.20 from ¥3,270,676,576.56, a reduction of 10.43%[28] - The company's total equity increased to ¥9,371,793,718.85 from ¥9,271,609,818.07, reflecting a growth of 1.08%[29] Cash Flow - The company's cash flow from operating activities was -¥436,673,090.75, a decrease of 205.77% compared to the same period last year[3] - Cash flow from operating activities shows a net outflow of -436,673,090.75, compared to -142,812,352.08 in the previous period, indicating a worsening cash flow situation[32] - The company received cash from investment activities totaling 4,754,090,112.22, compared to 7,661,136,503.58 in the previous period, indicating a decrease in investment inflows[32] - The net cash flow from financing activities is 180,044,633.76, a recovery from -316,812,088.02 in the previous period[33] Shareholder Information - The total number of common shareholders at the end of the reporting period was 67,903[10] - As of the report date, the controlling shareholder, BGI Holdings, pledged 10.375 million shares, accounting for 79.18% of its holdings and 24.80% of the total share capital[20] - The shareholder, Shenzhen Shenghua Investment, reduced its holdings by 1.2507 million shares, representing 0.2990% of the total share capital, as part of a planned reduction of up to 6.2748 million shares[23] - BGI Holdings transferred 16.7327 million shares at a price of 44.10 yuan per share, totaling approximately 738 million yuan, reducing its stake from 38.17% to 31.32%[24] Business Segments - The reproductive health business generated operating revenue of RMB 643 million, down 28.4% compared to RMB 899 million in the same period of 2024[17] - The non-invasive prenatal genetic testing business saw a revenue decline of approximately 36% year-on-year[17] - Revenue from the hereditary disease clinical diagnosis series in the tertiary prevention business grew by approximately 17% year-on-year[17] - The oncology and chronic disease prevention business achieved revenue of 358 million yuan, a decrease of 8.8% compared to 393 million yuan in the same period of 2024[18] - The infection prevention business reported revenue of 75 million yuan, a year-on-year increase of 41.7% from 53 million yuan in 2024, driven by the development of a pathogen sequencing platform and automation systems[18] - The multi-omics and synthesis business generated revenue of 452 million yuan, remaining stable compared to the previous year, with single-cell sequencing revenue growing approximately 93%[18] - The precision medicine testing comprehensive solution business achieved revenue of 1.124 billion yuan, an increase of 11.2% from 1.010 billion yuan in 2024, due to accelerated local clinical application and successful overseas market expansion[19] Expenses - The sales expenses decreased by 17.73%, management expenses decreased by 17.76%, and R&D expenses decreased by 16.38% during the reporting period[15] - Research and development expenses decreased to ¥332,812,703.86, a reduction of 16.43% compared to ¥398,014,771.10 in the previous period[30] Other Financial Metrics - The basic earnings per share were -¥0.0653, an increase of 81.08% year-on-year[3] - The weighted average return on equity was -0.29%, an increase of 1.14% compared to the previous year[3] - The company recorded an increase of RMB 82.11 million in credit impairment losses compared to the same period last year due to extended customer payment cycles[16] - The company incurred a tax expense of -19,791,439.13, compared to -2,842,029.91 in the previous period, indicating a higher tax burden despite losses[31]

基因合成，是指人工合成具有特定序列的较长双链DNA，是DNA合成业务的子集。基因合成是当前合成生物学的主要内容，通过基因合成，可以获得自然 界中不存在的基因，并为人类改造生物开辟了一个全新的方向。基因合成的类别主要包括柱式合成、微阵列合成及酶促合成等。 近年来，随着合成生物技术的重要性与日俱增，我国政府持续加大对该产业的支持力度，合成生物学逐渐被纳入国家战略新兴产业，并期望以此促进创新， 为基因合成行业提供了良好的政策环境和发展机遇。同时，我国基因测序、基因编辑技术等也在不断升级迭代，为基因合成行业的发展提供了有力的技术支 持。2023年，中国基因合成市场规模大约增至143亿元。 基因合成指透过化学或酶促方法，在实验室内人工合成基因或特定DNA序列的过程，该技术可精确设计及构建特定核苷酸序列的定制化基因，广泛应用于 基础研究、生物技术、基因治疗及合成生物学等多个领域。目前，我国基因合成主要应用于工业领域与研究领域。 本文节选自华经产业研究院发布的《2025年全球及中国基因合成行业现状及展望（附市场规模、细分结构及重点企业）「图」》，如需获取全文内容，可进 入华经情报网搜索查看。 深圳华大基因股份有限公司作为中 ...

格隆汇10月23日｜在第二十届国际基因组学大会（ICG-20）上，华大生命科学研究院与之江实验室联 合发布了全球首个百亿参数人类基因组通用基础模型——Genos。这一针对人类基因组深度优化的基因 组基础模型，可支持高达百万碱基对的超长上下文分析，并实现单碱基分辨率的精准识别。Genos的推 出标志着基因组研究从"读出"碱基序列迈向"读懂"生命底层逻辑的一次关键转折，有望为临床疾病诊 断、个人基因组解读及前沿科学研究带来突破性变革。据悉，Genos的相关成果已发表于国际学术期刊 GigaScience。 ...

Core Viewpoint - The company focuses on cognitive impairment diseases, particularly Alzheimer's disease, and has launched multiple blood testing products for Alzheimer's detection, integrating genetic testing for risk assessment and diagnosis [1] Company Summary - The company has developed a multi-dimensional testing solution that includes Alzheimer's blood tests and APOE gene risk assessments, aimed at risk evaluation, differential diagnosis, and medication guidance [1] - The increasing proportion of elderly population in the country is expected to drive the demand for chronic disease management, which will further enhance the need for genetic testing in personalized chronic disease management and risk warning [1] Industry Summary - The demand for chronic disease management is on the rise due to demographic changes, particularly the aging population, which is likely to boost the growth of genetic testing services [1]

Core Viewpoint - BGI Genomics stated on October 22 that its stock price in the secondary market is influenced by various factors including the capital market environment, macroeconomic conditions, and investor expectations [1] Group 1 - The company aims to continuously improve operational efficiency and management levels [1] - BGI Genomics is committed to solid business operations to enhance company performance [1] - The company strives to provide returns to its investors [1]